Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB

Απλή σελίδα τεκμηρίου
dc.contributor.authorTsimihodimos, V.en
dc.contributor.authorKarabina, S. A.en
dc.contributor.authorTambaki, A. P.en
dc.contributor.authorBairaktari, E.en
dc.contributor.authorGoudevenos, J. A.en
dc.contributor.authorChapman, M. J.en
dc.contributor.authorElisaf, M. S.en
dc.contributor.authorTselepis, A. D.en
dc.date.accessioned2015-11-24T19:34:22Z
dc.date.available2015-11-24T19:34:22Z
dc.identifier.issn1524-4636-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23618
dc.rightsDefault Licence-
dc.subject1-Alkyl-2-acetylglycerophosphocholine Esteraseen
dc.subjectAnticholesteremic Agents/*pharmacologyen
dc.subjectApolipoproteins B/blooden
dc.subjectApolipoproteins E/blooden
dc.subjectAryldialkylphosphataseen
dc.subjectCholesterol, LDL/metabolismen
dc.subjectEsterases/blooden
dc.subjectHeptanoic Acids/*pharmacologyen
dc.subjectHumansen
dc.subjectHyperlipidemias/*drug therapy/*metabolismen
dc.subjectLipoproteins, LDL/*blooden
dc.subjectMacrophages/secretionen
dc.subjectPhospholipases A/*drug effectsen
dc.subjectPyrroles/*pharmacologyen
dc.titleAtorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIBen
heal.abstractHuman plasma platelet-activating factor acetylhydrolase (PAF-AH) is a phospholipase A(2) that is primarily associated with low density lipoprotein (LDL). PAF-AH activity has also been found in high density lipoprotein (HDL), although it has recently been indicated that there is no PAF-AH protein in HDL. Plasma paraoxonase 1 (PON1) is an HDL-associated esterase, which also exhibits PAF-AH-like activity. The effect of atorvastatin (20 mg per day for 4 months) on PAF-AH and PON1 activities in patients with dyslipidemia of type IIA (n=55) or type IIB (n=21) was studied. In both patient groups, atorvastatin significantly reduced plasma PAF-AH activity because of the decrease in LDL plasma levels and the preferential decrease in PAF-AH activity on dense LDL subfractions (LDL-4 and LDL-5). Drug therapy did not affect HDL-associated PAF-AH activity or serum PON1 activities toward paraoxon and phenylacetate in either patient group. However, because of the reduction in LDL cholesterol levels, the ratios of HDL-associated PAF-AH and serum PON1 activities to LDL cholesterol levels were significantly increased after drug administration. The reduction of the LDL-associated PAF-AH activity and the elevation in the ratios of HDL-associated PAF-AH and PON1 activities to LDL plasma levels may represent a new dimension in the antiatherogenic effect of atorvastatin.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/11834533-
heal.journalNameArterioscler Thromb Vasc Biolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2002-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ